Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer
DOI: https://doi.org/10.2147/OTT.S400824
IF: 4
2023-04-01
OncoTargets and Therapy
Abstract:Revathi Badiginchala, 1 Palanki Satya Dattatreya, 1 Attili Venkata Satya Suresh, 1 Sharanabasappa Somanath Nirni, 1 Vindhya Vasini Andra, 1 Deepak Bunger, 2 Alok Chaturvedi 2 1 Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India; 2 Medical Affairs, Intas Pharmaceuticals Limited, Ahmedabad, India Correspondence: Revathi Badiginchala, Omega Hospitals, L/276A, Road Number 12, MLA Colony, Banjara Hills, Hyderabad, Telangana, 500034, India, Tel +8978698260, Email Objective: Nanosomal docetaxel lipid suspension (NDLS) is a novel formulation developed to overcome toxicity issues caused by excipients (polysorbate 80 and ethanol) present in commercially available docetaxel formulation. We conducted a prospective, observational study to compare the outcomes of nanosomal docetaxel lipid suspension (NDLS)-based versus conventional docetaxel-based chemotherapy in primary operable breast cancer. Methods: Sixty adult women with newly diagnosed stage IIb-III breast cancer were included. Patients received NDLS-based (n=30) or docetaxel-based (n=30) chemotherapy. Patients received (1) four cycles of preoperative doxorubicin and cyclophosphamide (AC) followed by four cycles of NDLS or docetaxel (T) and surgery (neoadjuvant AC→NDLS [n=9], or neoadjuvant AC→T [n=10]), or (2) four cycles of preoperative AC followed by surgery and postoperative NDLS or T (neoadjuvant AC→adjuvant NDLS [n=14], or neoadjuvant AC→adjuvant T [n=15]), or (3) surgery followed by postoperative AC→NDLS or T (adjuvant AC→NDLS [n=7], or adjuvant AC→T [n=5]) regimens. The study outcomes were pathological complete response (pCR) rates, clinical overall response rates (ORR), disease-free survival (DFS), overall survival (OS), and adverse event (AE) profile. Results: For neoadjuvant AC→T (n=10) vs neoadjuvant AC→NDLS (n=9), the pCR rates were 100% each, and the ORR were 100% vs 88.9% (p=1.0). All patients were alive at 6 months, and the median OS was not reached. Three patients had progressive disease (T: n=2, NDLS: n=1) with a DFS of 12 weeks in all three patients. Grade 3 infusion-related reactions were seen in five patients (16.7%) in T vs none in NDLS arms. Conclusion: NDLS-based neo/adjuvant chemotherapy was efficacious in the treatment of primary operable breast cancer and showed comparable pCR, ORR, DFS and OS rates versus conventional docetaxel. NDLS was better tolerated than conventional docetaxel. Keywords: NDLS, nanosomal docetaxel lipid suspension, docetaxel, breast cancer, operable Neoadjuvant chemotherapy (NACT) is considered the standard treatment option for early/locally advanced and primary operable breast cancer. 1 Achieving pathological complete response (pCR) after NACT is associated with improved survival benefits and is considered as a surrogate endpoint for survival outcomes. 2 The addition of taxanes to NACT has improved patient outcomes in clinical studies. 3–5 In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B27 study, the addition of docetaxel to neoadjuvant doxorubicin/cyclophosphamide therapy increased the pCR rate from 13.7% to 26.1%. 6 Docetaxel is a hydrophobic molecule, and hence, polysorbate 80, a synthetic nonionic surfactant, along with ethanol as diluent is used in the conventional docetaxel formulation. 7 Polysorbate 80 has been implicated in some adverse events (AEs) associated with drugs formulated with this vehicle. 8,9 Studies have linked polysorbate 80 with acute hypersensitivity reactions and cumulative fluid retention, peripheral neuropathy, severe anaphylactoid reactions, and infusion-site reactions, among others. 1,8,10–13 There are reports of alcohol intoxication in patients receiving conventional docetaxel. 14,15 Lipid-based nanoformulations can effectively increase the drug's water solubility, significantly improve drug membrane permeability and allow sustained drug release. 16 Nanosomal (<100nm) particles of NDLS, developed using the "NanoAqualip" technology, 13 may increase the systemic availability of docetaxel through enhanced permeability and retention in compromised tumor vasculature, and thus, overall improved therapeutic outcomes can be anticipated. 12 Nanosomal docetaxel lipid suspension (NDLS) is a novel lipid-based, polysorbate 80- and ethanol-free formulation of docetaxel, which was developed 13 to overcome the toxicity challenges generally associated with conventional docetaxel formulation. NDLS can obviate the need for premedication with corticosteroids because of its much lower risk of hypersensitivity compared with conventional docetaxel. 12,13 NDLS has demonstra -Abstract Truncated-
oncology,biotechnology & applied microbiology